Utilizing Simoa® technology, this study found that our commercially available plasma Simoa® ALZpath p-Tau 217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage. 

JAMA Neurology | January 22, 2024 

A recent study published in JAMA Neurology utilizing Simoa® technology to reveal groundbreaking Alzheimer’s research has been making waves in the news. The research conducted by Dr. Nicholas Ashton from the University of Gothenburg, affirmed that our commercially available plasma Simoa® ALZpath p-Tau217 immunoassay accurately detected biological Alzheimer’s Disease (AD) pathology and the results were comparable to those obtained using CSF biomarkers.  

It is exciting to see advancements in Alzheimer’s detection, especially with the validation and recognition of a blood-based Simoa® pTau217 test. Early detection can significantly impact treatment outcomes, and accessible testing methods play a crucial role in identifying Alzheimer’s in its early stages.  

Read the Full Study

News Roundup 

CNN: New blood test that screens for Alzheimer’s may be a step closer to reality, study suggests 

Med Page Today: Alzheimer’s Blood Test Shows High Diagnostic Accuracy — Commercial ptau-217 assay reduced confirmatory testing by about 80% 

The Hill: Alzheimer’s blood test could be used to screen even before symptoms: Study 

Euro News: Blood tests can diagnose Alzheimer’s as accurately as spinal punctures and better than brain scans 

Fox News: New test can detect Alzheimer’s disease up to 15 years before symptoms appear  

TIME: A Blood Test for Alzheimer’s Disease Is Almost Here 

Additional Resources: 

• Going Beyond Cerebrospinal Fluid (CSF) Biomarkers For Alzheimer’s Disease: Introducing Blood-Based Biomarker Detection 
  • Explore benefits of blood-based biomarkers such as p-Tau 217 compared to CSF biomarkers.  

• Simoa® ALZpath p-Tau 217 Advantage PLUS 

• • Take charge of your experiments with the Simoa® ALZpath p-Tau 217 Advantage PLUS assay kit (104570), designed for seamless implementation and precise p-Tau 217 quantification on the HD-X™. 

• Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test To Aid Physician Diagnosis Of Alzheimer’s Disease 

• • In October 2023, Lucent Diagnostics expanded its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease – LucentAD p-Tau 217. p-Tau 217 is a top performing biomarker for Alzheimer’s pathology, enabling clinical sensitivity and specificity in blood. 

• Accelerating Drug Approval With Simoa® Ultrasensitive Measurements Of Biomarkers 

• • See where it started. Join Dr. Milena Milutinovic from Quanterix and Dr. Nicholas Ashton from the University of Gothenburg for a webinar highlighting the role of Simoa® technology in the identification and validation of novel biomarkers. The discussion will then demonstrate how Simoa® technology is advancing neurological research and the clinical utility of blood-based biomarkers. Recorded in June of 2023.